Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Optimal Timing for Follow-up Mutation Testing in CML

January 14th 2015

Introduction: Role of Genetic Testing in CML

January 14th 2015

PD-1 Pathway Blockade May Shape the Future of Hodgkin Lymphoma Therapy

January 14th 2015

Agents that target components of the programmed death-1 (PD-1) pathway are poised to make an impact on the treatment of patients with hematologic malignancies, particularly Hodgkin lymphoma (HL).

Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

January 9th 2015

Final Thoughts on AML and ALL

January 9th 2015

New Treatments in Acute Myeloid Leukemia

January 9th 2015

Role of Transplant in Acute Myeloid Leukemia

January 9th 2015

Therapeutic Targets in Acute Lymphoblastic Leukemia

January 9th 2015

CAR-Modified T Cell Therapy in ALL

January 9th 2015

Blinatumomab in Acute Lymphoblastic Leukemia

January 9th 2015

Minimum Residual Disease in ALL

January 9th 2015

Asparaginase in Acute Lymphoblastic Leukemia

January 9th 2015

Chemotherapy Regimens in Patients With ALL

January 9th 2015

TKIs in Philadelphia Chromosome-Positive ALL

January 9th 2015

Vincristine in Acute Lymphoblastic Leukemia

January 9th 2015

Identifying Transplant Candidates in ALL

January 9th 2015

Induction Therapy in Adult Ph-negative ALL

January 9th 2015

Introduction: Understanding ALL and Its Prognostic Factors

January 9th 2015

Dr. Advani Compares Inotuzumab and Blinatumomab for ALL

January 8th 2015

Anjali Advani, MD ,staff physician, Department of Hematologic Oncology and Blood Disorders, Director, Inpatient Leukemia Program, Taussig Cancer Institute, associate professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, compares inotuzumab ozogamicin, a CD22 monoclonal antibody, to blinatumomab, a CD19 bi-specific anti-CD19/CD3 antibody for the treatment of acute lymphoblastic leukemia (ALL).

A Keen Mind and a Daring Spirit Propel Kantarjian's Many Discoveries in Leukemia Therapy

January 8th 2015

Hagop M. Kantarjian, MD, has built the nation's largest clinical leukemia practice, in part to ensure that leukemia studies are completed efficiently and in a timely manner.